GP方案和MVP方案治疗晚期非小细胞肺癌的疗效观察

Comparison between GP and MVP regimen for adanced Non-small cell lung cancer

关键词:  非小细胞肺癌  化疗  吉西他滨  长春花碱酰胺  顺铂

Key words:  non-small cell lung cancer  chemotherapy  gemcitabine  vindesine  cisplatin

摘要:

［目的］ 比较GP方案与MVP方案治疗非小细胞肺癌的疗效和毒性反应。［方法］ 75例非小细胞肺癌中，42例应用吉西他滨1.0 g/m 2第1、8天静脉滴注，顺铂25 mg/m 2第1～3天静脉滴注；33例应用丝裂霉素8 mg/m 2第1天静脉推注，长春花碱酰胺3 mg/m 2静脉滴注，顺铂25 mg/m 2第1～3天静脉滴注；同时给予水化，利尿等处理，21 d为1个周期，两个周期后评价疗效。［结果］　GP组CR 4例、PR 20例，RR 57.1%（24/42）；MVP组CR1例、PR 11例，RR 36.4%（12/33）。两者统计学分析差异有显著性（P<0.05）。骨髓抑制为吉西他滨和长春花碱酰胺的主要毒性反应，其中GP组血小板数下降高于MVP组（40.5%比27.3%）； MVP组白细胞数下降高于GP组（72.7%比50.0%），但差异无显著性（P>0.05）。GP方案比MVP方案治疗非小细胞肺癌，疗效显著，毒性可耐受。

Abstract:

［Objective］　To compare the efficacy and toxicity between GP (Gemcitabine + Cisplatin) regimen and MVP (Mitomycin+Vindesine + Cisplatin) regimen in the treatment of advanced Non-small Cell Lung Cancer. ［Methods］ Seventy-five cases of NSCLC were enrolled .Among them,42 cases were treated with GP regimen. (GEM 1.0 g/m 2 ivgtt d1,8, DDP 25　mg/m 2 ivgtt d 1-3). Of 33 cases were treated with MVP regimen　(MMC 8　mg/m 2 iv di,VDS 3　mg/m 2 ivgtt di,8 DDP 25　mg/m 2 ivgtt d 1-3).The patients in two groups were repeatedly treated every 3 weeks and evaluated the efficacy after 2 cycles. ［Results］ For the cases with GP regimen ,the overall response rate was 57.1% with complete response 4 cases and partial response 20 cases. For the cases with MVP regimen the overall response rate was 36.4% with complete response 1 case and with partial response 11 cases. There was significant difference between two groups (p<0.05). Major toxicity is myelosuppression. The thrombocytopenia for GP regimen is higher than MVP regimen (40.5% versus 27.3%). The leucocytopenia for MVP regimen is higher than GP regimen (72.7% versus 50.0 %) (p>0.05). ［Conclusion］ GP than MVP regimen for advanced NSCLC shows a good curative effect and low toxicity. It deserves further clinical application.